Results 121 to 130 of about 21,002 (186)

An overview of chronic myeloid leukemia and its animal models [PDF]

, 2015

core   +1 more source

Autophosphorylation of oncoprotein TEL-ABL in myeloid and lymphoid cells confers resistance to the allosteric ABL inhibitor asciminib. [PDF]

Sci Signal
Muratcioglu S, Eide CA, Hung CL, Gorday K, Sumpena E, Zuo W, Groves JT, Druker BJ, Kuriyan J.   +8 more
europepmc   +1 more source

Advances in Targeting BCR-ABL^T315I Mutation with Imatinib Derivatives and Hybrid Anti-Leukemic Molecules. [PDF]

Molecules
Tuzikiewicz A, Wawrzyniak W, Kutner A, Żołek T.   +3 more
europepmc   +1 more source

Natural Products Targeting BCR-ABL: A Plant-Based Approach to Chronic Myeloid Leukemia Treatment. [PDF]

Molecules
Pechlivani L, Giannakis A, Sioka C, Alexiou GA, Kyritsis AP.   +4 more
europepmc   +1 more source

An Automated Cartridge-Based Microfluidic System for Real-Time Quantification of <i>BCR::ABL1</i> Transcripts in Chronic Myeloid Leukemia: An Italian Experience. [PDF]

Int J Mol Sci
Danzero AC, Gottardi EM, Quarantelli F, Del Prete C, Potenza A, Venturi C, Berchialla P, Guerrini F, Bono C, Ottaviani E, Galimberti S, Fava C, Izzo B.   +12 more
europepmc   +1 more source

Lactate-mediated activation of GPR81 regulates BCR/Abl protein expression in chronic myeloid leukemia cells selected under low oxygen tension. [PDF]

J Pathol
Menegazzi G, Desideri D, Biagioni A, Rovida E, Dello Sbarba P, Peppicelli S.   +5 more
europepmc   +1 more source

BCR::ABL1-positive chronic myeloid leukaemia in a scenario of a remote diagnosis of JAK2-V617F-mutated polycythemia vera: a single patient experience with imatinib and ruxolitinib combination therapy. [PDF]

Ann Hematol
Bartolucci P, Gigli F, Tabanelli V, Valeriano A, Gregato G, Poletti C, Bertolini F, Derenzini E.   +7 more
europepmc   +1 more source

Under ONIOM Layers: Analysis of BCR-ABL Enzyme Inhibitors Through Bond-Critical Points and Natural Orbitals. [PDF]

Molecules
Rocha KML, Nascimento ÉCM, Martins JBL.
europepmc   +1 more source

Chronic Myeloid Leukemia and the T315I <i>BCR::ABL1</i> Mutation. [PDF]

Int J Mol Sci
Pierro F, Stella S, Fazio M, Russo S, Massimino M, Mirabile G, Belletti D, Allegra A, Stagno F.   +8 more
europepmc   +1 more source

Hypoxic conditions confer chemoresistance to crizotinib but not to imatinib in chronic myeloid leukemia cells. [PDF]

Hematol Transfus Cell Ther
Avinery L, Regev D, Khamaisi H, Gopas J, Mahajna J.   +4 more
europepmc   +1 more source